Leonard Zehr, Author at BioTuesdays

Developments

Anavex gets orphan drug status in Rett syndrome

The FDA has granted orphan drug designation to Anavex Life Sciences’ (NASDAQ:AVXL) ANAVEX 2-73 for the treatment of Rett syndrome. In a statement, Christopher Missling, president and CEO, said orphan drug designation...

May 20, 2016

Developments

FDA grants Profound Medical IDE approval for TULSA-PRO

Profound Medical (TSX-V:PRN) has received investigational device exemption (IDE) approval from the FDA for a multicenter pivotal clinical trial to evaluate the efficacy of the TULSA-PRO System in patients with localized...

May 19, 2016

Developments

BioLight expands portfolio with eye drops for DES

BioLight Life Sciences (TASE:BOLT) has obtained worldwide rights, excluding Israel and Italy, for the manufacturing, distribution, sales and marketing of a groundbreaking new eye drop product for the treatment of dry...

May 19, 2016

Markets

Roth ups Celator Pharma price target to $26

Roth Capital Partners has raised its price target for Celator Pharmaceuticals (NASDAQ:CPXX) to $26 from $22, after the company’s Vyxeos drug candidate received breakthrough therapy designation from the FDA. The stock...

May 19, 2016

Developments

Oramed posts positive oral insulin Phase 2b results

Oramed Pharmaceuticals (NASDAQ:ORMP) has reported positive top-line results from its Phase 2b study, designed to evaluate the safety and efficacy of its oral insulin capsule, ORMD-0801, in patients with Type 2 diabetes...

May 18, 2016

Feature

ARIAD hopes to launch second oncology drug in early 2017

By Len Zehr ARIAD Pharmaceuticals (NASDAQ:ARIA) is hoping to receive FDA approval to commercialize in early 2017 its second orphan oncology product, brigatinib, for the treatment of certain genetic forms of non-small...

May 17, 2016

Markets

Leerink downgrades Epirus Biopharma to market perform

Leerink Partners has downgraded Epirus Biopharmaceuticals (NASDAQ:PRS) to “market perform” from “outperform” and slashed its price target to 75 cents from $10. The stock closed at 78 cents on Friday. Analyst Jason...

May 16, 2016

Executive Moves

Nobilis Health appoints chief accounting officer

Nobilis Health (NYSE MKT:HLTH; TSX:NHC) has appointed Marcos Rodriguez as chief accounting officer. Mr. Rodriguez brings over 17 years of diversified accounting experience to the company. Prior to joining Nobilis, he...

May 16, 2016

Developments

Dipexium completes enrollment in second Phase 3 trial

Dipexium Pharmaceuticals (NASDAQ:DPRX) has completed patient enrollmentin the OneStep-1 pivotal Phase 3 clinical trial of its Locilex broad-spectrum, topical antibiotic peptide. Last week, the company reached the...

May 16, 2016

Markets

BioSight closes investment from Arkin, Primera

Closely-held BioSight has closed an investment of $13-million led by Mori Arkin’s pharmaceutical investment firm, Arkin Holdings, and the U.S.-based venture firm, Primera Capital. Proceeds will be used for a multi...

May 16, 2016

Author - Leonard Zehr

Anavex gets orphan drug status in Rett syndrome

FDA grants Profound Medical IDE approval for TULSA-PRO

BioLight expands portfolio with eye drops for DES

Roth ups Celator Pharma price target to $26

Oramed posts positive oral insulin Phase 2b results

ARIAD hopes to launch second oncology drug in early 2017

Leerink downgrades Epirus Biopharma to market perform

Nobilis Health appoints chief accounting officer

Dipexium completes enrollment in second Phase 3 trial

BioSight closes investment from Arkin, Primera

Subscribe